Tectonic Therapeutic, Inc. achieved positive results from Part B of the phase 1b study targeting pulmonary hypertension in heart failure with reduced ejection fraction (PH-HFrEF) patients. TECX is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback